Study Urges Flexibility in Quality Testing of FDA-Approved Drugs Launching in Developing Countries

Drugmakers breaking into emerging markets could see supply chain benefits and quicker product launches if these markets automatically registered FDA-approved products before testing for quality issues, according to a new study. Given the high quality of drugs approved by stringent regulatory authorities like the FDA, this approach would help focus attention on prior testing of drugs more likely to be substandard or counterfeit, according to the working paper published recently by the National Bureau of Economic Research.
Drug Industry Daily